» Articles » PMID: 11153962

Epidemiology of Schizophrenia: the Global Burden of Disease and Disability

Overview
Specialties Neurology
Psychiatry
Date 2001 Jan 12
PMID 11153962
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence from nearly a century of epidemiological research indicates that schizophrenia occurs in all populations with a prevalence in the range of 1.4 to 4.6 per 1000 and incidence rates in the range of 0.16-0.42 per 1000 population. Multi-centre studies conducted by the World Health Organization have highlighted important differences between 'Western' and 'Third World' populations as regards the course and outcome of the disorder, with a significantly better prognosis in the developing countries. The factors underlying the better outcome of schizophrenia in developing countries remain essentially unknown but are likely to involve interactions between genetic variation and specific aspects of the environment. These features place schizophrenia, along with diabetes, cancer and hypertension, into the group of genetically complex diseases which are characterised by polygenic transmission, locus heterogeneity and environmental contribution to causation. The emerging pattern of risk factors and antecedents of schizophrenia suggests multiple, mainly quantitative deviations from the average developmental trajectory, primarily in the areas of early neurodevelopment, cognitive ability and social behaviour. These deviations are compatible with the notion of non-specific background factors facilitating the operation of genetically determined causal pathways. Research likely to result in new insights should focus on the population distribution and behavioural effects of potential risk factors and markers suggested by biological and genetic research.

Citing Articles

Resting-State Functional Connectivity Explained Psychotic-like Experiences in the General Population and Partially Generalized to Patients and Relatives.

Ma Y, Hendrickson T, Ramsay I, Shen A, Sponheim S, MacDonald 3rd A Biol Psychiatry Glob Open Sci. 2023; 3(4):1094-1103.

PMID: 37881569 PMC: 10593874. DOI: 10.1016/j.bpsgos.2022.08.011.


Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes.

Lv Y, Wen L, Hu W, Deng C, Ren H, Bao Y Metab Brain Dis. 2023; 39(1):147-171.

PMID: 37542622 DOI: 10.1007/s11011-023-01271-x.


Association between polymorphism rs2421943 of the insulin-degrading enzyme and schizophrenia: Preliminary report.

Ambrozova L, Zeman T, Janout V, Janoutova J, Lochman J, Sery O J Clin Lab Anal. 2023; 37(13-14):e24949.

PMID: 37515308 PMC: 10492455. DOI: 10.1002/jcla.24949.


Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia.

Ballesteros J, Moreno-Calvete M, Santos-Zorrozua B, Gonzalez-Fraile E Cochrane Database Syst Rev. 2023; 7:CD013511.

PMID: 37490701 PMC: 10368081. DOI: 10.1002/14651858.CD013511.pub2.


How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients.

Fond G, Falissard B, Nuss P, Collin C, Duret S, Rabbani M Mol Psychiatry. 2023; 28(12):5328-5336.

PMID: 37479782 PMC: 11041650. DOI: 10.1038/s41380-023-02154-4.